Protein & Antibody World Congress 2023 Europe
London, United Kingdom
Day 1 - Monday 13th November 2023
- Potential applications on cellular pathway alteration at the protein level: targeted protein sequestration, protein recruitment, protein degradation, and selective
inhibition of binding interfaces - Biochemical, genetic, and technological challenges in genetic code engineering
PROTEIN AND ANTIBODY TECHNOLOGY
- Recent advances in computational/AI-based techniques for antibody engineering and discovery
- AI methods relevant for antibody development
- Computational antibody design procedures with emphasis to machine learning
- Examining the current biological and engineering challenges facing the biomanufacturing of antibodies
- Emerging technologies to reduce biomanufacturing challenges.
- Innovations in process analytical technologies and single use technologies to improve current performance of mAb production processes.
- Docking setup using the wrapper code approach to optimize the DOCK program for large-scale computation as well as docking analysis using variance and promiscuity
- Relevance of Small angle X-ray scattering (SAXS) for quantifying conformational flexibility in proteins
- Feasibility of MARS for the measurement of both protein purity-related and formulation-related PQAs
- Potential to be a powerful methodology to improve the efficiency of biopharmaceutical development and manufacturing
PROTEIN AND ANTIBODY METHODOLOGY
- Comprehensive overview of validated, forgotten and newly develop payloads with diverse procedures of action.
- Key role of Payload Diversification in the field of future ADC development
- Advantages of payloads and benefits of payload diversification
- Evolution of Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) targets for cancer therapy
- Use of scTRAIL and associated peptide linkers as promising strategy for antitumor therapeutics
- Steps in the process of antibody discovery and development
- Differences in developability analyses in discovery and development stages
- Developability-related considerations and assessment at the discovery stage
- Analysis and optimization of developability-related attributes
- Carbohydrates as promising targets for vaccine development against infectious disease
- Strategies on overcoming challenges carbohydrate-based vaccine design and development approaches targeting cancer and other diseases
- How can general protein language models efficiently evolve human antibodies?
- Could these models be applicable to evolving more unnatural, de novo designed proteins
- Comparison to other sequence-based methods
- Computational efficiency of this approach
- Leveraging data beyond protein sequence information including protein structure information and binding affinity data to further improve the outcome
